Structure Therapeutics is a dynamic, clinical-stage biotechnology company at the forefront of pharmaceutical innovation. By integrating advanced computational chemistry and precise molecular interaction visualization, the company specializes in developing novel, oral small molecule medicines designed to treat a wide array of chronic diseases. Their unique approach aims to combine the structural insights of traditional biology with the agility and scale of modern computational platforms.
Since going public in early 2023, Structure Therapeutics has continued to build on its reputation as a high-potential innovator backed by world-class life sciences investors. With operations strategically positioned in California and Shanghai, the company fosters a unique global perspective that enables them to attract top-tier talent and drive efficient, high-impact research programs aimed at improving patient lives worldwide.